Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.88 +5.03%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $16.00) while maintaining a Overweight rating.
You May Also Be Interested In
- JPMorgan Downgrades Mapletree Logistics Trust (MLT:SP) (MAPGF) to Neutral
- Envista Holdings Corp. (NVST) PT Lowered to $27 at UBS, Neutral Rating Maintained
- Discovery Silver Corp (DSV:CN) (DSVSF) PT Raised to Cdn$15 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
